Medication-assisted Treatment (MAT) Market Size

Request Free Sample Copy

Report ID: 5814
Published Date: Nov 28, 2025
Report Format: PDF, PPT

Buy Now

Medication-assisted Treatment (MAT) Market Outlook:

Medication-assisted Treatment (MAT) Market size was valued at USD 11.2 billion in 2025 and is set to exceed USD 26.03 billion by 2035, registering over 8.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of medication-assisted treatment is estimated at USD 12.09 billion.

This can be attributed to the rising prevalence of substance use disorder among individuals. According to recent information, around 286 Million people aged 15-64 used drugs worldwide in 2020, a 26 percent increase over the past decade.

In addition, with the advancement in medications and therapies such as the availability of a variety of medications like methadone, naltrexone. There is a continuous improvement in behavioral therapies and pharmacological treatments which is enhancing the efficacy of medication-assisted treatment. Moreover, the development of long-acting formulations and innovative delivery methods is also driving the medication-assisted treatment market growth.

Medication-assisted Treatment (MAT) Market Size

Browse key industry insights with market data tables & charts from the report:

Medication-assisted Treatment (MAT) Market Size & Share, Growth Trends 2035

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of medication-assisted treatment is estimated at USD 12.09 billion.

The global medication-assisted treatment market size crossed USD 11.2 billion in 2025 and is likely to register a CAGR of over 8.8%, exceeding USD 26.03 billion revenue by 2035.

By 2035, the North America region is projected to secure about 45% share in the medication-assisted Treatment Market, supported by intensified funding for MAT programs, expanded treatment capacity, and broader regulatory integration into mainstream healthcare owing to increased institutional backing.

Key players in the market include Indivior PLC, Mallinckrodt Pharmaceuticals, Titan Pharmaceuticals Inc., Alkermes plc, Orexo AB, Mylan N.V., Teva Pharmaceutical Industries Ltd., Lupin Limited, Hikma Pharmaceuticals PLC, Novartis AG.